RE: https://bsky.app/profile/did:plc:ucyautp3h3p3klrxkh4tsyc7/post/3mdxndx45vs2h
Sign-up form for the Virtual C...
RE: https://mstdn.science/@ChemBioTalks/116007334595611582
I am very happy that we again managed to invite two world-leading scientists as keynotes for the 6th Virtual @ChemBioTalks.
We are working on an exciting additional program. Stay tuned!
Mailing list: https://fd24.formdesk.com/universiteitleiden/VirtualChemBioTalks
We are very excited that Michelle Chang and Giulio Superti-Furga will be our keynote speakers at this year's Virtual ChemBioTalks on September 29th, 2026.
If you do not want to miss anything, sign up for our mailing list: https://fd24.formdesk.com/universiteitleiden/VirtualChemBioTalks
We are excited that the 5th Virtual #ChemBioTalks attracted 450 participants from 50 different countries world-wide. Thank you all for making this such an engaging event!
If you want to suggest speakers and keynotes for 2026, please do so by October 31st at [email protected]
We had amazing 5th Virtual #ChemBioTalks. Thank you to all the speakers and organizers for making this possible!
Already mark your calendars for the 6th edition on September 29th, 2026. You are invited to suggest speakers via [email protected].
Targeted protein degradation with proteolysis-targeting chimeras (PROTACs) has the potential to tackle disease-causing proteins that have historically been highly challenging to target with conventional small molecules. This article summarizes the first two decades of PROTAC discovery and discusses key areas for the future of this therapeutic modality, including establishing the target classes for which it is most suitable and extending its application beyond oncology.
Targeted protein degradation with proteolysis-targeting chimeras (PROTACs) has the potential to tackle disease-causing proteins that have historically been highly challenging to target with conventional small molecules. This article summarizes the first two decades of PROTAC discovery and discusses key areas for the future of this therapeutic modality, including establishing the target classes for which it is most suitable and extending its application beyond oncology.